PMID- 31353640
OWN - NLM
STAT- MEDLINE
DCOM- 20200612
LR  - 20200612
IS  - 1745-4514 (Electronic)
IS  - 0145-8884 (Linking)
VI  - 43
IP  - 2
DP  - 2019 Feb
TI  - The effects of hesperidin on sodium arsenite-induced different organ toxicity in 
      rats on metabolic enzymes as antidiabetic and anticholinergics potentials: A 
      biochemical approach.
PG  - e12720
LID - 10.1111/jfbc.12720 [doi]
AB  - In our work, it was purposed to investigate the effects of sodium arsenite (SA) 
      and hesperidin (HSP) administered to rats on some metabolic enzymes including 
      carbonic anhydrase (CA), aldose reductase (AR), paraoxonase-1 (PON1), 
      alpha-glycosidase (alpha-Gly), butyrylcholine esterase (BChE), acetylcholine esterase 
      (AChE) enzymes activities in the brain, heart, liver, testis, and kidney tissues 
      of rats. CA activities were significantly decreased in testis, liver, and heart 
      tissues of rats given HSP, SA, SA+HSP-100, and SA+HSP-200 compared to control 
      (p < 0.05). In liver tissue, AChE and BChE enzymes activities were significantly 
      reduced given in all groups. In all tissues, alpha-Gly activity was reduced given in 
      all groups. In the current study, aldose reductase enzyme activity was reduced 
      significantly in testis, brain, and heart tissues of all groups compared to 
      standard (p < 0.05). PON1 enzyme activity was increased significantly in kidney 
      and liver tissues of rats HSP groups and decreased SA groups compared to control. 
      PRACTICAL APPLICATIONS: alpha-Glycosidase is the key enzyme involved in the digestion 
      of the carbohydrate. Another enzyme alpha-amylase hydrolyzes the alpha-linked 
      polysaccharide derivatives into oligosaccharide molecules, and alpha-glycosidase 
      enzymes, which are characterized in small intestine, catalyze the final stage in 
      the digestive mechanism of carbohydrate molecule to release absorbable 
      monosaccharides like glucose. Conforming to the cholinergic hypothesis, 
      impairment of the cholinergic pathways plays a good role in the development of 
      neurodegenerative diseases like depression, schizophrenia, Alzheimer's disease 
      (AD) problems with the regulation of traumatic brain injury and sleep. The AD is 
      the main reason for dementia disease, and mild to moderate cases are generally 
      treated with AChE inhibitors. Human CA inhibitor compounds are clinically used 
      for more than 70 years as antiglaucoma and diuretics drugs.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - Caglayan, Cuneyt
AU  - Caglayan C
AUID- ORCID: 0000-0001-5608-554X
AD  - Department of Biochemistry, Faculty of Veterinary Medicine, Bingol University, 
      Bingol, Turkey.
FAU - Demir, Yeliz
AU  - Demir Y
AUID- ORCID: 0000-0003-3216-1098
AD  - Department of Chemistry, Faculty of Science, Ataturk University, Erzurum, Turkey.
FAU - Kucukler, Sefa
AU  - Kucukler S
AUID- ORCID: 0000-0002-8222-5515
AD  - Department of Biochemistry, Faculty of Veterinary Medicine, Ataturk University, 
      Erzurum, Turkey.
FAU - Taslimi, Parham
AU  - Taslimi P
AUID- ORCID: 0000-0002-3171-0633
AD  - Department of Chemistry, Faculty of Science, Ataturk University, Erzurum, Turkey.
FAU - Kandemir, Fatih Mehmet
AU  - Kandemir FM
AUID- ORCID: 0000-0002-8490-2479
AD  - Department of Biochemistry, Faculty of Veterinary Medicine, Ataturk University, 
      Erzurum, Turkey.
FAU - Gulcin, Ilhami
AU  - Gulcin I
AUID- ORCID: 0000-0001-5993-1668
AD  - Department of Chemistry, Faculty of Science, Ataturk University, Erzurum, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20181113
PL  - United States
TA  - J Food Biochem
JT  - Journal of food biochemistry
JID - 7706045
RN  - 0 (Arsenites)
RN  - 0 (Carbonic Anhydrase Inhibitors)
RN  - 0 (Cholinergic Antagonists)
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium Compounds)
RN  - 48OVY2OC72 (sodium arsenite)
RN  - E750O06Y6O (Hesperidin)
RN  - EC 1.1.1.21 (Aldehyde Reductase)
RN  - EC 3.1.1.7 (Acetylcholinesterase)
RN  - EC 3.1.1.8 (Butyrylcholinesterase)
RN  - EC 3.1.8.1 (Aryldialkylphosphatase)
RN  - EC 3.2.1.- (Glycoside Hydrolases)
RN  - EC 4.2.1.1 (Carbonic Anhydrases)
SB  - IM
MH  - Acetylcholinesterase/metabolism
MH  - Aldehyde Reductase/metabolism
MH  - Animals
MH  - Arsenites/*toxicity
MH  - Aryldialkylphosphatase/metabolism
MH  - Brain/drug effects/enzymology
MH  - Butyrylcholinesterase/metabolism
MH  - Carbonic Anhydrase Inhibitors/administration & dosage
MH  - Carbonic Anhydrases/metabolism
MH  - Cholinergic Antagonists/*administration & dosage
MH  - Cholinesterase Inhibitors/administration & dosage
MH  - Glycoside Hydrolases/metabolism
MH  - Heart/drug effects
MH  - Hesperidin/*administration & dosage
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Kidney/drug effects/enzymology
MH  - Liver/drug effects/enzymology
MH  - Male
MH  - Myocardium/enzymology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sodium Compounds/*toxicity
MH  - Testis/drug effects/enzymology
OTO - NOTNLM
OT  - hesperidin
OT  - in vivo
OT  - metabolic enzymes
OT  - rats
OT  - sodium arsenite
EDAT- 2019/07/30 06:00
MHDA- 2020/06/13 06:00
CRDT- 2019/07/30 06:00
PHST- 2018/08/15 00:00 [received]
PHST- 2018/10/03 00:00 [revised]
PHST- 2018/10/12 00:00 [accepted]
PHST- 2019/07/30 06:00 [entrez]
PHST- 2019/07/30 06:00 [pubmed]
PHST- 2020/06/13 06:00 [medline]
AID - 10.1111/jfbc.12720 [doi]
PST - ppublish
SO  - J Food Biochem. 2019 Feb;43(2):e12720. doi: 10.1111/jfbc.12720. Epub 2018 Nov 13.